BioXcel Therapeutics (BTAI) Expected to Post Quarterly Earnings on Tuesday

BioXcel Therapeutics (NASDAQ:BTAI) is anticipated to post its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $0.4850 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.01). The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.38 million. On average, analysts expect BioXcel Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioXcel Therapeutics Trading Up 4.2%

BioXcel Therapeutics stock traded up $0.04 during mid-day trading on Tuesday, hitting $0.88. The company’s stock had a trading volume of 234,996 shares, compared to its average volume of 1,126,792. The stock’s fifty day moving average is $1.08 and its two-hundred day moving average is $1.30. The firm has a market capitalization of $27.27 million, a PE ratio of -0.15 and a beta of 0.32. BioXcel Therapeutics has a 1 year low of $0.74 and a 1 year high of $8.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. purchased a new stake in shares of BioXcel Therapeutics in the 1st quarter valued at $50,000. Geode Capital Management LLC boosted its holdings in BioXcel Therapeutics by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after acquiring an additional 6,120 shares during the period. XTX Topco Ltd purchased a new stake in BioXcel Therapeutics during the second quarter worth about $42,000. Diversify Wealth Management LLC purchased a new stake in BioXcel Therapeutics during the second quarter worth about $27,000. Finally, Millennium Management LLC acquired a new stake in shares of BioXcel Therapeutics during the third quarter worth about $2,632,000. 30.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on BTAI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $11.00.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.